ClinicalTrials.gov
public full text
Public Domain
Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Neuroinflammation in Patients With OCD#1172533
- Effects of Ondansetron in Obsessive-compulsive and Tic Disorders#1214148
- Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder#980181
- Epidiolex in Obsessive Compulsive Disorder and Related Disorders#866718
- Rigidity in error monitoring: Altered oscillatory dynamics under speed and accuracy instructions in obsessive-compulsive disorder#427005
Record · ID 1214652
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive